Molecule
Cenegermin is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. It is available as eye drops and kits for ophthalmic use. MedsAcross supplies Cenegermin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis. OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis.
Source: US FDA prescribing information
Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.
Source: US FDA prescribing information
One drop of OXERVATE in the affected eye(s), 6 times per day at 2-hour intervals, for eight weeks. General Dosing Information Contact lenses should be removed before applying OXERVATE and may be reinserted 15 minutes after administration. If a dose is missed, treatment should be continued as normal, at the next scheduled administration. If more than one topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel or other viscous eye drops.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Patients should remove contact lenses before applying OXERVATE and wait 15 minutes after instillation of the dose before reinsertion. Use with Contact Lens Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration. Eye Discomfort OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.
Source: US FDA prescribing information
The most common adverse reactions (incidence >5%) are eye pain, ocular hyperemia, eye inflammation and increased lacrimation.
Source: US FDA prescribing information
Storage Store the weekly cartons containing OXERVATE vials in the freezer at or below -4°F (-20°C). Patient Storage Within 5 hours of delivery, store the weekly carton(s) containing OXERVATE vials in the refrigerator between 36°F to 46°F (2°C to 8°C) for up to 14 days. A vial opened for daily use may be stored in the original weekly carton in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature up to 77°F (25°C), for up to 12 hours. Do not shake the vials.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Cenegermin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Oxervate kit Cold chain | Domp farmaceutici | US FDA | Available on request |
| Oxervate 20 mcg/mL eye dropsOphthalmic Cold chain | Domp farmaceutici | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Cenegermin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Cenegermin, including Oxervate.
Yes. The US FDA first approved Cenegermin on 22 August 2018, according to Drugs@FDA.
Yes. Cenegermin has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Cenegermin must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Cenegermin is classified under ATC code S01XA24 (Cenegermin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.